Linked Life Data

20209610

Source:http://linkedlifedata.com/resource/pubmed/id/20209610

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20209610rdf:typepubmed:Citationlld:pubmed
pubmed-article:20209610lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C1513822lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0035168lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0278627lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C1880171lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0220647lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0677936lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0069717lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0671970lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0449695lld:lifeskim
pubmed-article:20209610lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:20209610pubmed:issue10lld:pubmed
pubmed-article:20209610pubmed:dateCreated2010-5-4lld:pubmed
pubmed-article:20209610pubmed:abstractTextDespite the widespread use of oxaliplatin-based regimens for colorectal and other gastrointestinal cancers, there is surprisingly little information regarding their empiric use for the treatment of carcinoma of unknown primary site (CUP). In the current study, the combination of oxaliplatin and capecitabine in patients with recurrent and refractory CUP was examined.lld:pubmed
pubmed-article:20209610pubmed:languageenglld:pubmed
pubmed-article:20209610pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20209610pubmed:citationSubsetAIMlld:pubmed
pubmed-article:20209610pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20209610pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20209610pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20209610pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20209610pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20209610pubmed:statusMEDLINElld:pubmed
pubmed-article:20209610pubmed:monthMaylld:pubmed
pubmed-article:20209610pubmed:issn0008-543Xlld:pubmed
pubmed-article:20209610pubmed:authorpubmed-author:HainsworthJoh...lld:pubmed
pubmed-article:20209610pubmed:authorpubmed-author:GrecoF...lld:pubmed
pubmed-article:20209610pubmed:authorpubmed-author:BurrisHoward...lld:pubmed
pubmed-article:20209610pubmed:authorpubmed-author:SpigelDavid...lld:pubmed
pubmed-article:20209610pubmed:authorpubmed-author:FarleyCindyClld:pubmed
pubmed-article:20209610pubmed:authorpubmed-author:BartonJohnJlld:pubmed
pubmed-article:20209610pubmed:authorpubmed-author:ShipleyDianna...lld:pubmed
pubmed-article:20209610pubmed:authorpubmed-author:Macias-PerezI...lld:pubmed
pubmed-article:20209610pubmed:copyrightInfo(c) 2010 American Cancer Society.lld:pubmed
pubmed-article:20209610pubmed:issnTypePrintlld:pubmed
pubmed-article:20209610pubmed:day15lld:pubmed
pubmed-article:20209610pubmed:volume116lld:pubmed
pubmed-article:20209610pubmed:ownerNLMlld:pubmed
pubmed-article:20209610pubmed:authorsCompleteYlld:pubmed
pubmed-article:20209610pubmed:pagination2448-54lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:meshHeadingpubmed-meshheading:20209610...lld:pubmed
pubmed-article:20209610pubmed:year2010lld:pubmed
pubmed-article:20209610pubmed:articleTitleOxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.lld:pubmed
pubmed-article:20209610pubmed:affiliationSarah Cannon Research Institute, Nashville, Tennessee 37203, USA. jhainsworth@tnonc.comlld:pubmed
pubmed-article:20209610pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20209610pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20209610pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:20209610pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed